# US 2025/0082750 A1 · Methods for treating atopic dermatitis by administering an il-4r antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082750 A1
- Document ID: US20250082750A1
- Status: Published application
- Kind: A1
- Application number: 18/776,820
- Filed: 2024-07-18
- Published: 2025-03-13
- Earliest claimed: 2019-08-05
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Ashish BANSAL; Neil GRAHAM; Paola MINA-OSORIO; John DAVIS; Mohamed KAMAL
- Web page: https://patentgrep.com/patent/US20250082750A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods for treating moderate-to-severe or severe atopic dermatitis in a pediatric subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

## Claims

### Claim 1

A method for treating atopic dermatitis (AD) or improving an AD-associated parameter in a subject, the method comprising:
(a) selecting a subject with moderate-to-severe or severe AD, wherein the subject is ≥6 years to <12 years of age; and
(b) administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, wherein the IL-4R antagonist is an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a subject with severe AD that cannot be adequately controlled with topical AD medications or for whom topical treatment is medically inadvisable.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject is inadequately responsive to treatment with a topical corticosteroid (TCS).

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is a subject with severe AD who is a candidate for systemic therapy.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject:
(i) has a baseline Investigator's Global Assessment (IGA) score=4;
(ii) has a baseline Eczema Area and Severity Index (EASI) score≥21;
(iii) has a baseline Body Surface Area (BSA) affected by AD≥15%; and/or
(iv) has chronic AD diagnosed at least one year prior to the onset of treatment.

### Claim 6 (depends on 1)

The method of claim 1, wherein the IL-4R antagonist is subcutaneously administered at an initial dose followed by one or more secondary doses, wherein each secondary dose is administered 1 to 4 weeks after the immediately preceding dose, and wherein:
(i) for a subject having a body weight of <30 kg, the initial dose of the IL-4R antagonist is 200 mg and each secondary dose is 100 mg; or
(ii) for a subject having a body weight of ≥30 kg, the initial dose of the IL-4R antagonist is 400 mg and each secondary dose is 200 mg; or
(iii) the initial dose of the IL-4R antagonist is 600 mg and each secondary dose is 300 mg.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject has a body weight of <30 kg and the IL-4R antagonist is administered at an initial dose of 200 mg followed by one or more secondary doses of 100 mg every two weeks (Q2W).

### Claim 8 (depends on 6)

The method of claim 6, wherein the subject has a body weight of ≥30 kg and the IL-4R antagonist is administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg every two weeks (Q2W).

### Claim 9 (depends on 6)

The method of claim 6, wherein the IL-4R antagonist is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg every four weeks (Q4W).

### Claim 10 (depends on 1)

The method of claim 1, wherein the IL-4R antagonist is subcutaneously administered at an initial dose followed by one or more secondary doses, wherein:
(i) or a subject having a body weight of <30 kg, the IL-4R antagonist is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q4W; or
(ii) for a subject having a body weight of ≥30 kg to <60 kg, the IL-4R antagonist is administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg Q2W; or
(iii) for a subject having a body weight of ≥60 kg, the IL-4R antagonist is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q2W.

### Claim 11 (depends on 10)

The method of claim 10, wherein the subject has a body weight of <30 kg and the IL-4R antagonist is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q4W.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject has a body weight of ≥15 kg to <30 kg.

### Claim 13 (depends on 10)

The method of claim 10, wherein the subject has a body weight of ≥30 kg to <60 kg and the IL-4R antagonist is administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg Q2W.

### Claim 14 (depends on 10)

The method of claim 10, wherein the subject has a body weight of ≥60 kg and the IL-4R antagonist is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q2W.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject has a concurrent allergic condition selected from the group consisting of allergic rhinitis, asthma, food allergy, allergic conjunctivitis, hives, chronic rhinosinusitis, nasal polyps, and eosinophilic esophagitis.

### Claim 16 (depends on 1)

The method of claim 1, wherein the IL-4R antagonist is administered in combination with a TCS.

### Claim 17 (depends on 16)

The method of claim 16, wherein the TCS is a medium-potency TCS.

### Claim 18 (depends on 16)

The method of claim 16, wherein the TCS is a low-potency TCS.

### Claim 19 (depends on 16)

The method of claim 16, wherein treatment with the IL-4R antagonist reduces the amount of TCS that is administered to the subject relative to baseline.

### Claim 20 (depends on 1)

The method of claim 1, wherein treatment with the IL-4R antagonist results in an improvement of an AD-associated parameter that is selected from:
(i) a reduction from baseline in IGA score to achieve an IGA score of 0 or 1 by week 16 after administration of the first dose of the IL-4R antagonist; and
(ii) a reduction of at least 75% from baseline in an EASI score (EASI-75) by week 16 after administration of the first dose of the IL-4R antagonist.

### Claim 21

A method for treating atopic dermatitis (AD) or improving an AD-associated parameter in a subject, the method comprising:
(a) administering a first dosing regimen of an IL-4R antagonist to a subject having moderate-to-severe AD or severe AD, wherein the subject is ≥6 years to <18 years of age;
(b) determining whether the subject has an inadequate clinical response to the first dosing regimen; and
(c) for a subject having an inadequate clinical response, administering a second dosing regimen of the IL-4R antagonist to the subject, wherein the second dosing regimen comprises administering the IL-4R antagonist at (i) a dose of 200 mg Q2W if the subject has a body weight <60 kg; or (ii) a dose of 300 mg Q2W if the subject has a body weight ≥60 kg; wherein the IL-4R antagonist is an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.

### Claim 22 (depends on 21)

The method of claim 21, wherein the determining step (b) comprises determining whether the subject has an IGA score ≥2 after at least 16 weeks of treatment with the first dosing regimen.

### Claim 23 (depends on 21)

The method of claim 21, wherein the first dosing regimen comprises administering the IL-4R antagonist at an initial dose of 600 mg followed by one or more secondary doses of 300 mg every four weeks (Q4W).

### Claim 24 (depends on 1)

The method of claim 1, wherein the IL-4R antagonist is subcutaneously administered at an initial dose followed by one or more secondary doses, wherein each secondary dose is administered 1 to 4 weeks after the immediately preceding dose, wherein:
(i) for a subject having a body weight of <30 kg, the initial dose of the IL-4R antagonist is 200 mg and each secondary dose is 100 mg; or
(ii) for a subject having a body weight of ≥30 kg, the initial dose of the IL-4R antagonist is 400 mg and each secondary dose is 200 mg; or
(iii) the initial dose of the IL-4R antagonist is 600 mg and each secondary dose is 300 mg;
and wherein the subject is concomitantly administered at least one topical corticosteroid (TCS).

### Claim 25 (depends on 24)

The method of claim 24, wherein the subject has a body weight of <30 kg and the IL-4R antagonist is administered at an initial dose of 200 mg followed by one or more secondary doses of 100 mg every two weeks (Q2W).

### Claim 26 (depends on 24)

The method of claim 24, wherein the subject has a body weight of ≥30 kg and the IL-4R antagonist is administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg every two weeks (Q2W).

### Claim 27 (depends on 24)

The method of claim 24, wherein the IL-4R antagonist is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg every four weeks (Q4W).

### Claim 28 (depends on 24)

The method of claim 24, wherein the at least one TCS is a medium-potency TCS or a low-potency TCS.

### Claim 29 (depends on 24)

The method of claim 24, wherein the subject exhibits, at week 16, at least one of the parameter improvements selected from the group consisting of:
(a) a decrease in total SCORAD score of at least about 60% from baseline;
(b) a decrease in percentage of BSA affected by AD of at least about 67% from baseline;
(c) a decrease in objective SCORAD score of at least about at least about 57% from baseline;
(d) a decrease in SCORAD pruritis VAS score of at least about 67% from baseline; and
(e) a decrease in SCORAD sleep loss VAS score of at least about 70% from baseline.

### Claim 30

A method for treating AD or improving an AD-associated parameter in a subject, wherein the subject is ≥6 years to <18 years of age and has moderate-to-severe or severe AD, the method comprising subcutaneously administering to the subject an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the HCDRs of a HCVR comprising the amino acid sequence of SEQ ID NO: 1 and the LCDRs of a LCVR comprising the amino acid sequence of SEQ ID NO:2; wherein:
(i) for a subject having a body weight of ≥15 kg to <30 kg, the anti-IL-4R antibody or antigen-binding fragment thereof is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q4W; or
(ii) for a subject having a body weight of ≥30 kg to <60 kg, the anti-IL-4R antibody or antigen-binding fragment thereof is administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg Q2W; or
(iii) for a subject having a body weight of ≥60 kg, the anti-IL-4R antibody or antigen-binding fragment thereof is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q2W.

### Claim 31 (depends on 30)

The method of claim 30, wherein the subject is ≥6 years to <12 years of age.

### Claim 32 (depends on 30)

The method of claim 30, wherein the subject is a candidate for systemic therapy.

### Claim 33 (depends on 1)

The method of claim 1, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3; the HCDR2 comprises the amino acid sequence of SEQ ID NO:4; the HCDR3 comprises the amino acid sequence of SEQ ID NO:5; the LCDR1 comprises the amino acid sequence of SEQ ID NO:6; the LCDR2 comprises the amino acid sequence of LGS; and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 34 (depends on 1)

The method of claim 1, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 1 and comprises a LCVR comprising the amino acid sequence of SEQ ID NO:2.

### Claim 35 (depends on 1)

The method of claim 1, wherein the anti-IL-4R antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

### Claim 36 (depends on 1)

The method of claim 1, wherein the IL-4R antagonist is dupilumab or a bioequivalent thereof.

### Claim 37 (depends on 1)

The method of claim 1, wherein the IL-4R antagonist is contained in a container selected from the group consisting of a glass vial, a syringe, a pre-filled syringe, a pen delivery device, and an autoinjector.

### Claim 38 (depends on 37)

The method of claim 37, wherein the IL-4R antagonist is contained in a pre-filled syringe.

### Claim 39 (depends on 38)

The method of claim 38, wherein the pre-filled syringe is a single-dose pre-filled syringe.

### Claim 40 (depends on 37)

The method of claim 37, wherein the IL-4R antagonist is contained in an autoinjector.

### Claim 41 (depends on 37)

The method of claim 37, wherein the IL-4R antagonist is contained in a pen delivery device.

### Claim at position 42

42-47. (canceled)

### Claim 48

A therapeutic dosage form of a pharmaceutical composition comprising an IL-4R antagonist, wherein administration of the dosage form for 16 weeks to a subject provides a mean serum concentration of the IL-4R antagonist of 80-100 mg/L.

### Claim 49 (depends on 48)

The therapeutic dosage form of claim 48, wherein the therapeutic dose of the IL-4R antagonist is 200 mg administered every two weeks.

### Claim 50 (depends on 48)

The therapeutic dosage form of claim 48, wherein the therapeutic dose of the IL-4R antagonist is 300 mg administered every four weeks.

### Claim 51 (depends on 48)

The therapeutic dosage form of claim 48, wherein the subject is >6 years to <18 years of age.

### Claim 52 (depends on 48)

The therapeutic dosage form of claim 48, wherein the IL-4R antagonist is an anti-IL-4R antibody or antigen-binding fragment thereof that comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:3, an HCDR2 comprising the amino acid sequence of SEQ ID NO:4, an HCDR3 comprising the amino acid sequence of SEQ ID NO:5, an LCDR1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of LGS, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8.

### Claim 53 (depends on 52)

The therapeutic dosage form of claim 52, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 1 and comprises a LCVR comprising the amino acid sequence of SEQ ID NO:2.
